financetom
Business
financetom
/
Business
/
Alphabet races toward $4 trillion valuation as AI-fueled gains accelerate
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Alphabet races toward $4 trillion valuation as AI-fueled gains accelerate
Nov 24, 2025 8:06 AM

(Reuters) -Alphabet closed in on a $4 trillion valuation on Monday, set to become only the fourth company to enter the exclusive club, as the Google parent rides an artificial intelligence-driven rally.

Shares of the company rose more than 5% to hit a record high of $315.9, giving it a market capitalization of $3.82 trillion. The stock has climbed nearly 70% so far this year, far outperforming AI rivals Microsoft ( MSFT ) and Amazon.com ( AMZN ).

Nvidia ( NVDA ), Microsoft ( MSFT ) and Apple ( AAPL ) have previously hit a $4 trillion valuation. Only Nvidia ( NVDA ) and Apple ( AAPL ) remain on the list currently.

The surge reflects a striking reversal in sentiment toward Alphabet after some investors feared the company had lost its AI edge to OpenAI after the 2022 launch of ChatGPT, even though it invented much of the underlying technology behind generative AI.

Alphabet has regained momentum this year by turning its cloud business, once an also-ran, into a key growth driver, drawing in Warren Buffett's Berkshire Hathaway as an investor and winning strong early reviews for its new Gemini 3 model.

Still, the milestone may fan fears about surging valuations that some business leaders warn have detached market movements from business fundamentals, sparking worries of a bubble reminiscent of the dot-com boom of the 1990s.

A wave of circular deals involving OpenAI and Nvidia ( NVDA ) - two of the companies at the heart of the AI boom - have also amplified the fears.

Still, analysts believe Google is well-positioned in the AI race, thanks to its strong cash flow, in-house chips that serve as an alternative to Nvidia's ( NVDA ) pricey processors and a sprawling internet search business that is already benefiting from AI integration.

(Reporting by Zaheer Kachwala and Aditya Soni in Bengaluru; Editing by Sriraj Kalluvila)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pelangio Exploration Upsizes Private Placement of Units to $4.5 Million
Pelangio Exploration Upsizes Private Placement of Units to $4.5 Million
Sep 24, 2025
12:59 PM EDT, 09/24/2025 (MT Newswires) -- Pelangio Exploration ( PGXPF ) on Wednesday said it upsized a non-brokered private placement of share units to $4.5 million from $4 million. The units will be priced at $0.18 each and consist of one share and half a two-year warrant to buy a share at $0.31. Proceeds will be used for exploration...
Congo sticking to cobalt export quotas, keen to boost processing
Congo sticking to cobalt export quotas, keen to boost processing
Sep 24, 2025
NEW YORK, Sept 24 (Reuters) - Democratic Republic of Congo will stick to its recently announced quota system for cobalt exports, with revisions only possible in the long term if the government sees them as necessary, the country's mining minister said on Wednesday. The mining minister, Louis Watum Kabamba, told Reuters in an interview on the sidelines of a seminar...
Update: Cidara's Phase 3 Trial of Influenza Prevention Drug CD388 to Begin in September; Shares Rise
Update: Cidara's Phase 3 Trial of Influenza Prevention Drug CD388 to Begin in September; Shares Rise
Sep 24, 2025
01:38 PM EDT, 09/24/2025 (MT Newswires) -- (Updates with stock price movement in the headline and the first paragraph.) Cidara Therapeutics ( CDTX ) shares rose more than 22% in recent Wednesday trading after the company said it will start enrolling patients for a phase 3 trial of CD388 by the end of September following its end-of-phase 2 meeting with...
Update: UniQure's Shares Soar After Phase 1/2 Trial in Huntington's Disease Meets Primary Endpoint
Update: UniQure's Shares Soar After Phase 1/2 Trial in Huntington's Disease Meets Primary Endpoint
Sep 24, 2025
01:39 PM EDT, 09/24/2025 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.) UniQure's ( QURE ) shares rose past 234% in recent Wednesday trading after the company said that its phase 1/2 study in Huntington's disease met its primary endpoint, with high-dose AMT-130 showing statistically significant 75% slowing of disease at 36 months as measured...
Copyright 2023-2025 - www.financetom.com All Rights Reserved